Q-Heal | Accelerated Wound Healing | Crassula Cosmeceutical
Crassula Cosmeceutical Division · QuanticSphere™ PQNS

Q-Heal
Accelerated
Wound Healing

A Clinically Inspired, Multi-Targeted Topical Therapy for Accelerated Wound Healing. Randomized clinical trial — 110 subjects — proven superior to comparator.

"Regenerative healing, clinically accelerated."

Clinical Results View Formulation
Q-HEAL wound healing spray application
0
Subjects
Randomized Clinical Trial
0%
Healing Score Reduction
Primary Endpoint
0 days
Near-Complete
Healing Duration
0
Serious Adverse
Events Reported
Q-HEAL healing formulation

Executive Summary

Next-Generation
Wound Healing Therapy

Conventional antiseptic and antibiotic-based topical agents primarily focus on infection control, often neglecting tissue regeneration, collagen remodeling, and long-term scar quality.

Accelerated Healing
Earlier and more pronounced improvement across all assessment timepoints
Reduced Pain & Inflammation
Many patients pain-free by Day 3–5; earlier resolution of swelling and erythema
Superior Cosmetic Outcomes
Thinner, fainter scars — supporting balanced collagen remodeling
Well Tolerated
No serious adverse events — suitable for outpatient and post-surgical use
Q-Heal is a next-generation topical wound healing formulation engineered to address the full biological cascade of wound repair through a synergistic combination of clinically relevant bioactives.

1. Clinical Background & Unmet Need

The Problem with
Standard Wound Treatments

Acute wounds — including surgical incisions and superficial abrasions — generally heal predictably; however, suboptimal management can result in significant complications.

Delayed Epithelial Closure
Suboptimal wound management slows the natural re-epithelialization process.
Prolonged Inflammation
Chronic inflammatory states impair tissue regeneration and increase complication risk.
Secondary Infection Risk
Inadequate antimicrobial coverage increases bacterial and fungal contamination.
Hypertrophic Scarring
Poor collagen remodeling leads to visible, thick, or raised scar formation.

Drawbacks of Standard Treatments

Irritate healing tissue — delaying natural repair processes
Delay epithelial migration — slowing wound closure
Contribute to antimicrobial resistance — a growing clinical concern
There is a clear clinical need for regenerative, anti-inflammatory, and antimicrobial therapies that promote both functional and cosmetic healing.

2. Formulation & Scientific Rationale

Multi-Pathway Wound
Healing Architecture

Q-Heal is designed as a multi-pathway wound healing system, integrating regenerative, anti-inflammatory, antimicrobial, antioxidant, and moisturizing mechanisms through a synergistic formulation.

Centella Asiatica Triterpenoids
Regenerative & Collagen Synthesis
Madecassic acid, Asiatic acid, Madecassoside, Asiaticoside — promote fibroblast proliferation, angiogenesis, collagen synthesis, and controlled remodeling.
Beta-Sitosterol & Glycyrrhizin
Anti-Inflammatory & Antioxidant
Potent anti-inflammatory and antioxidant activity — reduction of cytokine-mediated tissue damage and oxidative stress.
Terpinen-4-ol · Alpha-Monolaurin · Lauric Acid · Anthraquinone
Broad-Spectrum Antimicrobial
Comprehensive protection against bacterial and fungal contamination — without inducing antimicrobial resistance.
Collagen & Chondroitin Sulphate + SAPINEODERM®
Structural Repair & Barrier Restoration
Structural support for ECM formation, moisture retention, epithelial migration, and long-term skin barrier restoration.
This formulation architecture enables simultaneous control of inflammation, microbial burden, and tissue regeneration — rather than single-mechanism symptom control.

3. Clinical Trial Overview

Randomized Controlled Trial —
110 Subjects, 20 Days

Study Design
Type
Randomized, comparator-controlled, parallel-group clinical trial
Population
Adults ≥18 years with surgical or superficial abrasive wounds
Sample
110 subjects — Q-Heal group: n = 55 · Comparator group: n = 55
Application
Twice daily topical use
Duration
Up to 20 days (cosmetic follow-up to Day 30)
Clinical Endpoints
Primary
  • ≥90% reduction in composite Healing Score
  • Speed and quality of re-epithelialization
Secondary
  • ≥50% Healing Score reduction
  • Pain (VAS), swelling, redness
  • Discharge & malodour
  • Scar quality and cosmetic outcome
  • Safety and tolerability

4. Clinical Results

Earlier, Superior Healing
Across All Parameters

4.1 Healing Score Reduction Timeline

D3
Day 3
Early Pain & Inflammation Relief
Early reduction in pain, redness, and swelling. Many patients reporting pain relief by Day 3–5.
D5
Day 5
≥50% Healing Score Reduction
Majority of Q-Heal subjects achieved the ≥50% secondary endpoint. Faster slough clearance observed.
D12
Day 12
≥90% Healing Score Reduction
Majority achieved the ≥90% primary endpoint — far ahead of the comparator group's progression.
D20
Day 20
Near-Complete Healing
Near-complete healing in almost all Q-Heal subjects. Comparator showed residual symptoms and slower progression.

4.2 Parameter-Specific Outcomes

Slough Clearance
Faster clearance with Q-Heal — often by Day 5
Inflammation
Earlier resolution of swelling and erythema
Pain (VAS)
Rapid decline — many pain-free by Day 3–5
Discharge & Malodour
Earlier normalization and dryness
Tenderness
Reduced earlier, improving patient comfort
Scar Quality
Thinner, fainter scars vs comparator
Healing Score Reduction — Q-Heal vs Comparator

5. Safety, Positioning & Clinical Relevance

Proven Safe, Clinically
Superior, Market-Ready

Q-Heal demonstrated an outstanding safety profile with no serious adverse events. Compared with commonly used wound products (Healex, Bepanthen Plus, Hansaplast, Herbal creams), Q-Heal demonstrated clear clinical superiority.

No Serious Adverse Events
Throughout the full 20-day trial period.
Mild, Transient Sensations
Rare itching/warmth — self-resolving.
No Discontinuations
100% study completion due to adverse effects.
No Infection Events
No infections attributable to Q-HEAL.
Clinical Value
  • Faster healing reduces complication risk
  • Early pain relief improves adherence
  • Superior cosmetic outcomes
  • Broad: chronic wounds, diabetic ulcers, surgical recovery
Market Differentiation
  • Clinically proven vs comparator
  • Multi-targeted regenerative positioning
  • Spray format — hygienic, touch-free
  • Unique: regenerative bioactives + antimicrobial
This randomized clinical trial confirms that Q-Heal is a safe, effective, and clinically superior topical wound healing therapy — advancing wound care beyond conventional antiseptic paradigms.
Q-HEAL clinical wound healing therapy

Regenerative Healing,
Clinically Accelerated

Q-Heal is a scientific-grade regenerative topical therapy designed to accelerate wound healing, control inflammation, and improve cosmetic outcomes — leveraging multi-target bioactives and advanced delivery technology for safe, effective tissue repair across acute and chronic wounds.

Contact the Medical Team